SEC Filing Summary: Ventrus Biosciences, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ventrus Biosciences, Inc. on July 19, 2011. The report discloses the closing of an underwritten registered offering of common stock. Note: The metadata provided lists "Assembly Biosciences, Inc.," but the filing text explicitly identifies the registrant as "Ventrus Biosciences, Inc."
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses solely on the completion of a capital raise event.
Material Changes
- Capital Raise: The company closed an offering of 5,175,000 shares of common stock.
- Over-Allotment: The total share count includes 675,000 shares sold pursuant to the full exercise of the underwriters' over-allotment option.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors. It references a press release (Exhibit 99.1) for further details on the offering but does not include the text of that release within this document.
Investor Verification Checklist
- Verify the exact offering price per share and total gross proceeds, as these figures are not stated in the 8-K text.
- Review the attached press release (Exhibit 99.1) for details on the use of proceeds and underwriting discounts.
- Confirm the post-offering share count and dilution impact on existing shareholders.
- Check subsequent filings for the actual cash inflow recorded from this transaction.